结核分枝杆菌潜伏感染相关抗原的研究进展

doi:10.3969/j.issn.1000-6621.2014.03.013

摘要/Abstract

摘要： 结核病是全世界范围内危害人类健康的主要传染病之一。结核分枝杆菌潜伏感染者是结核病的主要来源，早期发现、诊断并有效治疗潜伏感染是有效控制结核病蔓延的重要措施之一。目前，结核分枝杆菌潜伏感染抗原主要包括与结核分枝杆菌缺氧、营养缺乏及与结核分枝杆菌复苏、再激活相关的蛋白。有些潜伏感染相关抗原具有良好的T细胞免疫能力，尤其更易在被潜伏感染人群中识别，有望成为新型的结核分枝杆菌潜伏感染诊断标志物及潜伏感染候选疫苗；有些潜伏感染相关抗原对B淋巴细胞具有较强免疫原性，在结核病体液免疫诊断方面有潜在诊断价值。这些潜伏感染相关蛋白在未来结核分枝杆菌潜伏疫苗及诊断试剂开发中具有良好的应用前景。

关键词: 分枝杆菌, 结核, 细菌蛋白质类, 监控蛋白类, 抗原, 细菌, 磷酸果糖激酶类

Abstract: Tuberculosis (TB) is one of the major threats to human health worldwide. Mycobacterium tuberculosis (Mtb) latent infection is a major source of tuberculosis infection. Early detection, diagnosis and effective treatment of latent infection are the important measures to effectively control the spread of TB. Currently, the Mycobacterium tuberculosis latent infection-associated antigens include hypoxia, nutritional deficiencies and proteins related to resuscitation and reactivation. Some latent infection-associated antigens have the ability of T-cell-mediated immunity, especially more vulnerable to be recognized by latent infection populations, are expected to become a new type of Mtb latent infection diagnostic marker and vaccine candidates; some latent infection-associated antigens have strong B lymphocytes immunogenicity, are expected to have potential diagnostic value in tuberculosis diagnosis. These latent infection-associated proteins have good prospects on latent tuberculosis vaccines and diagnostic reagents in the future.

Key words: Mycobacterium tuberculosis, Bacterial proteins, Chaperonins, Antigens, bacterial, Phosphofructokinases

白雪娟，吴雪琼. 结核分枝杆菌潜伏感染相关抗原的研究进展[J]. 中国防痨杂志, 2014, 36(3): 204-210. doi: 10.3969/j.issn.1000-6621.2014.03.013

BAI Xue-juan，WU Xue-qiong. Research progress of Mycobacterium tuberculosis latency-associated antigens[J]. Chinese Journal of Antituberculosis, 2014, 36(3): 204-210. doi: 10.3969/j.issn.1000-6621.2014.03.013

参考文献

［1］Gideon HP, Flynn JL. Latent tuberculosis: what the host “sees”? J Immunol Res,2011,50(2/3):202-212.
［2］Centers for Disease Control and Prevention,USA［EB/OL］.［2012-03-13］.http://www.cdc.gov/tb/publications/LTBI/intro.htm.
［3］陈心春,廖明凤,朱秀云,等.结核菌特异性IFN-γ Elispot检测在活动性结核病和结核感染诊断中的应用.中国防痨杂志,2010,32（11）：747-751.
［4］Wu X, Liang Y, Wang L, et al. Latent tuberculosis infection among new recruits to the army in Beijing, China in 2009. APMIS, 2011,119(6):377-384.
［5］Voskuil MI, Schnappinger D, Visconti KC, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med,2003,198(5):705-713.
［6］Betts JC, Lukey PT, Robb LC, et al. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol,2002,43(3):717-731.
［7］Laboratory of Stewart Cole, Ecole Polytechnique Fédérale de Lausanne And Swiss Institute of Bioinformatics［EB/OL］.［2012-03-13］. http://tuberculist.epfl.ch/.
［8］Converse PJ, Karakousis PC, Klinkenberg LG, et al. Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models.Infect Immun,2009,77(3):1230-1237.
［9］Park HD, Guinn KM, Harrell MI, et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol,2003,48(3):833-843.
［10］Roberts DM, Liao RP, Wisedchaisri G, et al. Two sensor kinases contribute to the hypoxic response of Mycobacterium tuberculosis. J Biol Chem, 2004, 279(22):23082-23087.
［11］Saini DK, Malhotra V, Dey D, et al. DevR-DevS is a bona fide two-component system of Mycobacterium tuberculosis that is hypoxia-responsive in the absence of the DNA-binding domain of DevR. Microbiology, 2004,150(Pt 4):865-875.
［12］Chakravorty S, Pathak D, Dudeja M, et al. PCR amplification of shorter fragments from the devR (Rv3133c) gene significantly increases the sensitivity of tuberculosis diagnosis. FEMS Microbiol Lett, 2006,257(2):306-311.
［13］Fu X, Jiao W, Abulimiti A, et al. Inter-subunit cross-linking suppressed the dynamic oligomeric dissociation of Mycobacterium tuberculosis Hsp16.3 and reduced its chaperone activity. Biochemistry (Mosc),2004,69(5):552-557.
［14］徐芳,张万江.结核分枝杆菌小分子热休克蛋白Hsp16.3功能及与结核病的关系研究进展.中国病原生物学杂志,2011,6(10):776-778.
［15］Yuan Y, Crane DD, Simpson RM, et al. The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci U S A,1998,95(16):9578-9583.
［16］师长宏,张延芬,朱德生,等.结核分枝杆菌热休克蛋白16.3及其合成肽诱导小鼠免疫应答的研究.中华结核和呼吸杂志,2009,32(8):603-607.
［17］陈玲霞.过表达结核分枝杆菌HspX蛋白的重组卡介苗的保护效应.武汉：华中科技大学,2011.
［18］罗泰来.表达Rv2031c-Rv2626c融合蛋白重组耻垢分枝杆菌的生物学和免疫学特性研究.西安：第四军医大学,2012.
［19］Khera A, Singh R, Shakila H, et al. Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis. Vaccine,2005,23(48/49):5655-5665.
［20］Jackett PS, Bothamley GH, Batra HV, et al. Specificity of antibodies to immunodominant mycobacterial antigens in pulmonary tuberculosis. J Clin Microbiol,1988,26(11):2313-2318.
［21］Raja A, Uma Devi KR, Ramalingam B, et al. Immunoglobulin G, A, and M responses in serum and circulating immune complexes elicited by the 16-kilodalton antigen of Mycobacterium tuberculosis.Clin Diagn Lab Immunol,2002,9(2):308-312.
［22］Demissie A, Leyten EM, Abebe M, et al. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol,2006,13(2):179-186.
［23］Black GF, Thiel BA, Ota MO, et al. Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol,2009,16(8):1203-1212.
［24］Reece ST, Nasser-Eddine A, Dietrich J, et al. Improved long-term protection against Mycobacterium tuberculosis Beijing/W in mice after intra-dermal inoculation of recombinant BCG expressing latency associated antigens. Vaccine,2011,29(47):8740-8744.
［25］Bivas-Benita M, Lin MY, Bal SM, et al. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine,2009,27(30):4010-4017.
［26］Riano F, Arroyo L, París S, et al. T cell responses to DosR and Rpf proteins in actively and latently infected individuals from Colombia. Tuberculosis (Edinb),2012,92(2):148-159.
［27］Honaker RW, Stewart A, Schittone S, et al. Mycobacterium bovis BCG vaccine strains lack narK2 and narX induction and exhibit altered phenotypes during dormancy. Infect Immun,2008,76(6):2587-2593.
［28］Bretl DJ, He H, Demetriadou C, et al. MprA and DosR coregulate a Mycobacterium tuberculosis virulence operon encoding Rv1813c and Rv1812c. Infect Immun,2012,80(9):3018-3033.
［29］Bertholet S, Ireton GC, Kahn M, et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol,2008,181(11):7948-7957.
［30］Bertholet S, Ireton GC, Ordway DJ, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med,2010,2(53):53-74.
［31］Roupie V, Romano M, Zhang L, et al. Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun,2007,75(2):941-949.
［32］Bashir N, Kounsar F, Mukhopadhyay S, et al. Mycobacterium tuberculosis conserved hypothetical protein rRv2626c modulates macrophage effector functions. Immunology,2010,130(1):34-45.
［33］Azzurri A, Kanaujia GV, Sow OY, et al. Serological markers of pulmonary tuberculosis and of response to anti-tuberculosis treatment in a patient population in Guinea. Int J Immunopathol Pharmacol,2006,19(1):199-208.
［34］Gennaro ML, Affouf M, Kanaujia GV, et al. Antibody mar-kers of incident tuberculosis among HIV-infected adults in the USA: a historical prospective study. Int J Tuberc Lung Dis,2007,11(6):624-631.
［35］Chiacchio T, Petruccioli E, Vanini V, et al. Higher frequency of T-cell response to M. tuberculosis latency antigen Rv2628 at the site of active tuberculosis disease than in peripheral blood. PLoS One,2011,6(11):e27539.
［36］Goletti D, Butera O, Vanini V, et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J,2010,36(1):135-142.
［37］Gordon SV, Eiglmeier K, Garnier T, et al. Genomics of Mycobacterium bovis. Tuberculosis (Edinb),2001,81(1/2):157-163.
［38］熊志红,庄玉辉,李国利.差显技术分析结核杆菌H37Rv与H37Ra差异表达的基因.微生物学通报,2005,3(2):57-61.
［39］李邦印,孙卫国,程小星,等.Rv2653c在大肠埃希菌中的克隆与表达研究.中国防痨杂志,2010,32(11):752-755.
［40］Aagaard C, Brock I, Olsen A, et al. Mapping immune reacti-vity toward Rv2653 and Rv2654: two novel low-molecular-mass antigens found specifically in the Mycobacterium tuberculosis complex. J Infect Dis,2004,189(5):812-819.
［41］Govender L, Abel B, Hughes EJ, et al. Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine,2010,29(1):51-57.
［42］Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med,2011,17(2):189-194.
［43］Schuck SD, Mueller H, Kunitz F, et al. Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection. PLoS One,2009,4(5):e5590.
［44］Mollenkopf HJ, Grode L, Mattow J, et al. Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis. Infect Immun,2004,72(11):6471-6479.

[1]	沈静，赵雁林，逄宇，张舜，杜昌廷，刘洁. 131株耐多药结核分枝杆菌对利福布丁与利福平交叉耐药的研究[J]. 中国防痨杂志, 2015, 37(4): 377-382.
[2]	刘银萍，王全立，张俊仙，梁艳，阳幼荣，白雪娟，吴雪琼. 结核分枝杆菌Rv1419蛋白抗原表位的预测[J]. 中国防痨杂志, 2015, 37(1): 52-55.
[3]	冉兵，蔡林. 基因芯片检测耐利福平结核分枝杆菌准确性的Meta分析[J]. 中国防痨杂志, 2015, 37(1): 56-65.
[4]	阳幼荣，吴雪琼. 结核分枝杆菌早期分泌抗原靶6家族其他蛋白抗原的研究进展[J]. 中国防痨杂志, 2014, 36(6): 503-508.
[5]	郄霜张立戴振华赵平杨锡琴郭兰芹修冰水陈堃王国华张贺秋冯晓燕. 结核分枝杆菌融合抗原38F和64F诊断活动性肺结核的价值[J]. 中国防痨杂志, 2013, 35(9): 643-648.
[6]	李强赵冰夏辉欧喜超傅衍勇王撷秀王海英彭琳李辉赵雁林. 结核分枝杆菌特异性蛋白（TB-SA）抗体检测试剂在结核病诊断中的应用研究[J]. 中国防痨杂志, 2013, 35(9): 693-696.
[7]	邱奕赵善民师长宏史皆然. 复苏促生长因子结构域及其突变体重组蛋白诱导小鼠免疫应答的研究[J]. 中国防痨杂志, 2013, 35(5): 331-336.
[8]	柴雪敏黎友伦. 结核分枝杆菌Ag85复合物相关疫苗研究进展[J]. 中国防痨杂志, 2013, 35(4): 282-285.
[9]	卢锦标杨蕾付丽丽陈保文都伟欣王国治徐苗. 结核亚单位疫苗AEC/BC-C02诱导小鼠长期的抗原特异性细胞应答[J]. 中国防痨杂志, 2013, 35(1): 32-36.
[10]	许婉华黄业伦刘燕文胡丽环罗少珍孟繁荣刘志辉. 培养滤液MPT64抗原检测结核分枝杆菌复合群生长的效能分析[J]. 中国防痨杂志, 2012, 34(8): 542-545.
[11]	邢爱英刘忠泉刘洋贾红彦李自慧郑晓静曹廷明杜凤娇杜博平古淑香张宗德. 结核分枝杆菌Rpf-DNA疫苗对Mtb感染小鼠免疫保护作用的研究[J]. 中国防痨杂志, 2012, 34(8): 532-537.
[12]	孙毅凡李海成周杰钱明陈涛江勇赖赛麟江振友钟球周琳. 结核分枝杆菌Rv3803c、Rv3846基因的克隆、表达、纯化与鉴定[J]. 中国防痨杂志, 2012, 34(8): 523-526.
[13]	李志达泽蛟章国平李瑞营刘万波苏娟张颖祝秉东. 结核分枝杆菌ESAT6-RpfE亚单位疫苗的构建与免疫原性研究[J]. 中国防痨杂志, 2012, 34(3): 154-160.
[14]	蒲江陶立峰邓海清王德海. 重组结核分枝杆菌ESAT6-CFP10蛋白对不同分枝杆菌致敏豚鼠的皮试反应研究[J]. 中国防痨杂志, 2012, 34(10): 676-680.
[15]	金海霞付雷王彬郑梅琴陆宇. 结核分枝杆菌利福平依赖性的初步研究[J]. 中国防痨杂志, 2012, 34(10): 670-675.